title: Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans.
abstract: Methamphetamine abuse is a significant public health concern. Although widely studied in laboratory animals, little is known about the abuse-related behavioral effects of methamphetamine relative to other abused stimulants in controlled laboratory settings in humans. The aim of this study was to examine the discriminative stimulus, subject-rated, performance, and cardiovascular effects of methamphetamine in humans. In the present study, subjects first learned to discriminate 10 mg of oral methamphetamine from placebo. After acquiring the discrimination (> or = 80% drug-appropriate responding on four consecutive sessions), a range of oral doses of methamphetamine (2.5-15 mg), d-amphetamine (2.5-15 mg), methylphenidate (5-30 mg), and triazolam (0.0625-0.375 mg) was tested. Methamphetamine functioned as a discriminative stimulus and produced prototypical stimulant-like subject-rated effects. d-Amphetamine and methylphenidate produced dose-related increases in methamphetamine-appropriate responding, whereas triazolam did not. d-Amphetamine and methylphenidate produced stimulant-like behavioral effects, whereas triazolam produced sedative-like effects. Methamphetamine, but no other drug, increased heart rate, systolic pressure, and diastolic pressure significantly above placebo levels. Performance in the Digit-Symbol Substitution Test was not affected by any of the drugs tested. Overall, these results demonstrate that the acute behavioral effects of methamphetamine, d-amphetamine, and methylphenidate overlap extensively in humans, which is concordant with findings from preclinical studies. Future studies should assess whether the similarity in the behavioral effects of methamphetamine and related stimulants can be extended to other behavioral assays, such as measures of reinforcement, in humans.
authors.affiliation: Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, KY 40536-0086, USA.
authors.forename: Rajkumar J
authors.initials: RJ
authors.lastname: Sevak
authors.forename: William W
authors.initials: WW
authors.lastname: Stoops
authors.forename: Lon R
authors.initials: LR
authors.lastname: Hays
authors.forename: Craig R
authors.initials: CR
authors.lastname: Rush
mesh_terms: D014151:Anti-Anxiety Agents / Q000494:pharmacology; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000494:pharmacology; D003913:Dextroamphetamine / Q000494:pharmacology*; D003971:Diastole / Q000187:drug effects; D004192:Discrimination, Psychological / Q000187:drug effects / Q000502:physiology*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D008694:Methamphetamine / Q000494:pharmacology*; D008774:Methylphenidate / Q000494:pharmacology*; D012201:Reward; D012680:Sensitivity and Specificity; D011795:Surveys and Questionnaires; D013599:Systole / Q000187:drug effects; D014229:Triazolam / Q000494:pharmacology*; D055815:Young Adult
chemical_list: D014151:Anti-Anxiety Agents; D000697:Central Nervous System Stimulants; D006993:Hypnotics and Sedatives; D014229:Triazolam; D008774:Methylphenidate; D008694:Methamphetamine; D003913:Dextroamphetamine